28938 Federal Register / Vol. 74, No. 116 / Thursday, June 18, 2009 / Notices 

DATES: Submit written comments on the 

collection of information by July 20, 

2009. 

ADDRESSES: Submit written comments 

on the collection of information by fax 

202.395.6974 to the OMB Desk Officer 

for AoA, Office of Information and 

Regulatory Affairs, OMB. 

FOR FURTHER INFORMATION CONTACT: 

Yvonne Jackson; Director; Office for 

American Indian, Alaskan Native and 

Native Hawaiian Programs; 

Administration on Aging; Washington, 

DC, 20201; (202) 357–3501; 

Yvonne.Jackson@aoa.hhs.gov. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, AoA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. AoA is requesting 

a continuation of an existing collection 

for Annual Program Performance 

Reports for Older Americans Act Title 

VI grantees. Information from the Title 

VI Program Performance Report 

provides a data base for AoA to (1) 

monitor program achievement of 

performance objectives; (2) establish 

program policy and direction; and (3) 

prepare responses to Congress, the 

OMB, the U.S. Government 

Accountability Office, other federal 

departments, and public and private 

agencies as required by the OAA Title 

II sections 202(a)19 and 208; and (4) 

prepare data for the Federal Interagency 

Task Force on Older Indians established 

pursuant to section 134(d) of the 1987 

Amendments to the OAA. If AoA did 

not collect the program data herein 

requested, it would not be able to 

monitor and manage total program 

progress as expected, nor develop 

program policy options directed toward 

assuring the most effective use of 

limited Title VI funds. Reports are due 

annually on June 30th. AoA submits an 

annual report to Congress and the 

reporting data is included in that report. 

Estimated Number of Responses: 246. 

Total Estimated Burden Hours: 615. 

In the Federal Register of April 8, 

2009 (Vol. 74, No. 66, Pages 15984– 

15985), the agency requested comments 

on the proposed collection of 

information. No comments were 

received. 

Dated: June 12, 2009. 

Edwin L. Walker, 

Acting Assistant Secretary for Aging. 

[FR Doc. E9–14348 Filed 6–17–09; 8:45 am] 

BILLING CODE 4154–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60 Day–09–0595] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. 

Alternatively, to obtain a copy of the 

data collection plans and instrument, 

call 404–639–5960 and send comments 

to Maryam I. Daneshvar, CDC Reports 

Clearance Officer, 1600 Clifton Road 

NE., MS–D74, Atlanta, Georgia 30333; 

comments may also be sent by e-mail to 

omb@cdc.gov. 

Comments are invited on (a) whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarify of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of information technology. Written 

comments should be received within 60 

days of this notice. 

Proposed Project 

The Model Performance Evaluation 

Program for HIV Rapid Testing (MPEP 

HIV–RT) (OMB Control No. 0920–0595, 

expiration date 3/31/2010)—Revision— 

National Center for Preparedness, 

Detection, and Control of Infectious 

Diseases (NCPDCID), Centers for Disease 

Control and Prevention (CDC). 

Brief Description and Background 

To support CDC’s mission of 

improving public health and preventing 

disease through continuously improving 

laboratory practices, CDC is requesting 

approval from the Office of Management 

and Budget (OMB) to continue data 

collection activities of the HIV rapid 

testing performance evaluation program 

(MPEP HIV RT) and to make changes to 

the results form. 

This program offers external 

performance evaluation (PE) twice a 

year for rapid HIV tests approved by the 

U.S. Food and Drug Administration 

(FDA). Examples of such tests are the 

OraQuick ADVANCE Rapid HIV–1⁄2

Antibody Test, the Uni-Gold 

Recombigen HIV test, the Clearview HIV 

1⁄2 STAT–PAK, the Clearview 

COMPLETE HIV 1⁄2, and the MedMira 

Reveal G3 Rapid HIV–1 Antibody Test. 

Participation in PE programs is expected 

to lead to improved HIV testing 

performance because participants have 

the opportunity to identify areas for 

improvement in their testing practices. 

This program helps to ensure accurate 

HIV rapid testing which is the 

foundation for HIV prevention and 

intervention programs. 

This program offers laboratories/ 

testing sites opportunities for: 

(1) Assuring that the laboratories/ 

testing sites are providing accurate test 

results through external quality 

assessment 

(2) Improving testing quality through 

self-evaluation in a non-regulatory 

environment 

(3) Testing well characterized samples 

from a source outside the test kit 

manufacturer 

(4) Discovering potential testing 

problems so that laboratories/testing 

sites can adjust procedures to reduce 

and eliminate errors 

(5) Comparing individual laboratory/ 

testing site results to others at the 

national and international level, and 

(6) Consulting with CDC staff to 

discuss testing issues. 

Program participants receive PE 

samples twice each year and report 

testing results to CDC. In addition to 

conducting the performance evaluation, 

participants in the MPEP HIV Rapid 

Testing program are required to 

complete a biennial (every other year) 

laboratory practices questionnaire. The 

burden for the Laboratory Practices 

Questionnaire has been adjusted for the 

average per year, since respondents 

complete the survey every two years. 

CDC does not charge any fees to sites 

participating in this external quality 

assessment program. 

There is no cost to respondents to 

participate in this program. 

Federal Register / Vol. 74, No. 116 / Thursday, June 18, 2009 / Notices 28939 

ESTIMATED ANNUALIZED BURDEN HOURS

Respondents Number 

of respondents 

Number of responses per 

respondent 

Average burden per response (in 

hours) 

Total burden 

(in hours) 

Labs ................................................................................................................. 660 2 10/60 220 

Labs ................................................................................................................. 330 1 30/60 165 

Total .......................................................................................................... ........................ ........................ ........................ 385 

Dated: June 11, 2009. 

Maryam I. Daneshvar, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. E9–14312 Filed 6–17–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60 Day-09–0600] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. 

Alternatively, to obtain a copy of the 

data collection plans and instrument, 

call 404–639–5960 and send comments 

to Maryam I. Daneshvar, CDC Reports 

Clearance Officer, 1600 Clifton Road, 

NE., MS–D74, Atlanta, Georgia 30333; 

comments may also be sent by e-mail to 

omb@cdc.gov. 

Comments are invited on (a) whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have a 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarify of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of information technology. Written 

comments should be received within 60 

days of this notice. 

Proposed Project 

Model Performance Evaluation 

Program for Mycobacterium tuberculosis 

and Non-tuberculous Mycobacterium 

Drug Susceptibility Testing (OMB 

Control No. 0920–0600, expiration date 

03/31/2010)—Revision—National 

Center for Preparedness, Detection, and 

Control of Infectious Diseases 

(NCPDCID), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

As part of the continuing effort to 

support both domestic and global public 

health objectives for treatment of 

tuberculosis (TB), prevention of multidrug resistance, and surveillance 

programs, CDC is requesting approval 

from the Office of Management and 

Budget to continue data collection from 

participants in the Model Performance 

Evaluation Program for Mycobacterium 

tuberculosis and Non-tuberculous 

Mycobacterium Drug Susceptibility 

Testing. This request includes changes 

to the Results Form and re-introduction 

of the Laboratory Practices 

Questionnaire. 

While the overall number of cases of 

TB in the U.S. has decreased, rates still 

remain high among foreign-born 

persons, prisoners, homeless 

populations, and individuals infected 

with HIV in major metropolitan areas. 

The rate of TB cases detected in foreignborn persons has been reported to be 

more than nine times higher than the 

rate among the U.S. born population. 

CDC’s goal to eliminate TB will be 

virtually impossible without 

considerable effort in assisting heavy 

disease burden countries in the 

reduction of tuberculosis. The Model 

Performance Evaluation Program for 

Mycobacterium tuberculosis and Nontuberculous Mycobacterium Drug 

Susceptibility Testing program supports 

this role by monitoring and evaluating 

the level of performance and practices 

among national and international 

laboratories performing M. tuberculosis 

susceptibility testing. Participation in 

this program is one way laboratories can 

ensure high-quality laboratory testing, 

resulting in accurate and reliable testing 

results. 

By providing an evaluation program 

to assess the ability of the laboratories 

to test for drug resistant M. tuberculosis 

and selected strains of Non-tuberculous 

Mycobacteria (NTM), laboratories also 

have a self-assessment tool to aid in 

optimizing their skills in susceptibility 

testing. The information obtained from 

laboratories on susceptibility testing 

practices and procedures is used to 

establish variables related to good 

performance, assessing training needs, 

and aid with the development of 

practice standards. 

Participants in this program include 

domestic clinical and public health 

laboratories and international 

laboratories. Data collection from 

domestic laboratory participants occurs 

twice per year. Data collection from 

international laboratories is limited to 

those that have public health 

responsibilities for tuberculosis drug 

susceptibility testing and have obtained 

approval to participate by their national 

tuberculosis program. The data 

collected in this program will include 

the susceptibility test results of primary 

and secondary drugs, drug 

concentrations, and test methods 

performed by laboratories on a set of 

performance evaluation (PE) samples. 

The PE samples are sent to participants 

twice a year. Participants also report 

demographic data such as laboratory 

type and the number of tests performed 

annually. Participants report this data 

every two years. The burden for the 

Laboratory Practices Questionnaire has 

been adjusted for the average per year, 

since responses are received every other 

year. 

There is no cost to respondents to 

participate other than their time.